Literature DB >> 367793

Acebutolol in hypertension: relationships between drug concentration and effects.

M A Martin, F C Phillips, G T Tucker, A J Smith.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 367793     DOI： 10.1007/bf00716378

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  24 in total

Review 1.  Effect of active drug metabolites on plasma level-response correlations.

Authors:  A J Atkinson; J M Strong
Journal:  J Pharmacokinet Biopharm       Date:  1977-04

2.  Effect of route of administration on the relationship between -adrenergic blockade and plasma propranolol level.

Authors:  C R Cleaveland; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1972 Mar-Apr       Impact factor: 6.875

3.  Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases.

Authors:  F R Bühler; J H Laragh; L Baer; E D Vaughan; H R Brunner
Journal:  N Engl J Med       Date:  1972-12-14       Impact factor: 91.245

4.  Lack of correlation between acetylator status and the production of the acetyl metabolite of acebutolol in man.

Authors:  A Gulaid; I M James; C M Kaye; O R Lewellen; E Roberts; M Sankey; J Smith; R Templeton; R J Thomas
Journal:  Br J Clin Pharmacol       Date:  1978-03       Impact factor: 4.335

5.  Acebutolol metabolite plasma concentration during chronic oral therapy.

Authors:  R A Winkle; P J Meffin; W B Ricks; D C Harrison
Journal:  Br J Clin Pharmacol       Date:  1977-10       Impact factor: 4.335

6.  Pathophysiologic and pharmacokinetic determinants of the antihypertensive response to propranolol.

Authors:  M Esler; A Zweifler; O Randall; V DeQuattro
Journal:  Clin Pharmacol Ther       Date:  1977-09       Impact factor: 6.875

7.  Controlled trial of acebutolol in hypertension.

Authors:  L Hansson; G Berglund; O Andersson; M Holm
Journal:  Eur J Clin Pharmacol       Date:  1977-10-14       Impact factor: 2.953

8.  Anti-hypertensive effect of acebutolol: its relation to sympathetic nervous system responsiveness and to plasma renin and dopamine-beta-hydroxylase activities.

Authors:  A Fournier; J M Hardin; J M Alexandre; M Lombaert; G Ronco; J F Bezoc; G Desmet; J Quichaud
Journal:  Clin Sci Mol Med Suppl       Date:  1976-12

9.  Suppression of premature ventricular contractions by acebutolol.

Authors:  A H Gradman; R A Winkle; J W Fitzgerald; P J Meffin; J Stoner; P A Bell; D C Harrison
Journal:  Circulation       Date:  1977-05       Impact factor: 29.690

10.  Beta-blockers and plasma renin activity in hypertension.

Authors:  G S Stokes; M A Weber; I R Thornell
Journal:  Br Med J       Date:  1974-01-12
View more
  5 in total

Review 1.  Acebutolol. A review of its pharmacological properties and therapeutic efficacy in hypertension, angina pectoris and arrhythmia.

Authors:  B N Singh; W R Thoden; A Ward
Journal:  Drugs       Date:  1985-06       Impact factor: 9.546

2.  Antihypertensive effect of diacetolol in essential hypertension.

Authors:  M Thibonnier; C Flabeau; M Thouvenin; A Roux; B Flouvat; P Pasquier; J Menard
Journal:  Br J Clin Pharmacol       Date:  1982-04       Impact factor: 4.335

3.  Observations on the clinical pharmacology and plasma concentrations of diacetolol, the major human metabolite of acebutolol.

Authors:  K Ohashi; S J Warrington; C M Kaye; G W Houghton; M Dennis; R Templeton; P Turner
Journal:  Br J Clin Pharmacol       Date:  1981-10       Impact factor: 4.335

4.  Antihypertensive action of acebutolol (Sectral) when used concomitantly with hydrochlorothiazide.

Authors:  P A Mitenko; J K McKenzie; J J Brossard
Journal:  Br J Clin Pharmacol       Date:  1982-02       Impact factor: 4.335

5.  Concentration-effect relationships for oxprenolol in patients with essential hypertension.

Authors:  G T McInnes; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1988-05       Impact factor: 4.335
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.